Publicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (15)

2022

  1. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

2019

  1. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546

2016

  1. Effect of pravastatin on the survival of patients with advanced gastric cancer

    Oncotarget, Vol. 7, Núm. 4, pp. 4379-4384

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Novel equation to determine the hepatic triglyceride concentration in humans by MRI: Diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery

    BMC Medicine, Vol. 12, Núm. 1

2013

  1. Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. MicroRNAs in biliary diseases

    World Journal of Gastroenterology, Vol. 18, Núm. 43, pp. 6189-6196

2010

  1. Adaptación en el intestino corto: efecto de la nutrición enteral mínima y los probióticos sobre la proliferación y la apoptosis en la pared intestinal.

    Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica, Vol. 23, Núm. 2, pp. 118-121

  2. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method

    World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499

  3. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  4. Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287

2009

  1. Características clinicopatológicas y supervivencia de los pacientes con cáncer de esófago. Resultados de 200 casos consecutivos

    Medicina Clinica, Vol. 133, Núm. 18, pp. 689-693

2008

  1. Resveratrol inhibits nonalcoholic fatty liver disease in rats

    BMC Gastroenterology, Vol. 8

2006

  1. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice

    BMC Gastroenterology, Vol. 6